  Changes in genetic and/or environmental factors to developing neural circuits
and subsequent synaptic functions are known to be a causative underlying the
varied socio-emotional behavioural patterns associated with autism spectrum
disorders (ASD). Seven transmembrane G protein-coupled receptors (GPCRs)
comprising the largest family of cell-surface receptors, mediate the transfer
of extracellular signals to downstream cellular responses. Disruption of GPCR
and their signalling have been implicated as a convergent pathologic mechanism
of ASD. Here, we aim to review the literature about the 23 GPCRs that are
genetically associated to ASD pathology according to Simons Foundation Autism
Research Initiative (SFARI) database such as oxytocin (OXTR) and vasopressin
(V1A, V1B) receptors, metabotropic glutamate (mGlu5, mGlu7) and
gamma-aminobutyric acid (GABAB) receptors, dopamine (D1, D2), serotoninergic
(5-HT1B and additionally included the 5-HT2A, 5-HT7 receptors for their strong
relevance to ASD), adrenergic ($\beta$2) and cholinergic (M3) receptors,
adenosine (A2A, A3) receptors, angiotensin (AT2) receptors, cannabinoid (CB1)
receptors, chemokine (CX3CR1) receptors, orphan (GPR37, GPR85) and olfactory
(OR1C1, OR2M4, OR2T10, OR52M1) receptors. We discussed the genetic variants,
relation to core ASD behavioural deficits and update on pharmacological
compounds targeting these 23 GPCRs. Of these OTR, V1A, mGlu5, D2, 5-HT2A, CB1,
and GPR37 serve as the best therapeutic targets and have potential towards core
domains of ASD pathology. With a functional crosstalk between different GPCRs
and converging pharmacological responses, there is an urge to develop novel
therapeutic strategies based on multiple GPCRs to reduce the socioeconomic
burden associated with ASD and we strongly emphasize the need to prioritize the
increased clinical trials targeting the multiple GPCRs.
